Compare PHVS & TGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHVS | TGLS |
|---|---|---|
| Founded | 2015 | 1984 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2020 | 2011 |
| Metric | PHVS | TGLS |
|---|---|---|
| Price | $33.56 | $44.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | $41.82 | ★ $63.33 |
| AVG Volume (30 Days) | ★ 331.1K | 233.3K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.41% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | ★ $370,984,000.00 |
| Revenue This Year | N/A | $13.56 |
| Revenue Next Year | N/A | $9.04 |
| P/E Ratio | ★ N/A | $62.07 |
| Revenue Growth | N/A | ★ 17.98 |
| 52 Week Low | $16.72 | $37.52 |
| 52 Week High | $35.33 | $83.32 |
| Indicator | PHVS | TGLS |
|---|---|---|
| Relative Strength Index (RSI) | 61.64 | 57.44 |
| Support Level | $24.73 | $44.26 |
| Resistance Level | N/A | $46.65 |
| Average True Range (ATR) | 1.61 | 1.70 |
| MACD | 0.17 | 0.10 |
| Stochastic Oscillator | 64.53 | 64.44 |
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.